
Tata Chemicals (TATACHEM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
37.2B
Gross Profit
25.3B
68.11%
Operating Income
3.7B
9.92%
Net Income
3.2B
8.50%
EPS (Diluted)
₹9.89
Balance Sheet Metrics
Total Assets
377.8B
Total Liabilities
152.8B
Shareholders Equity
225.0B
Debt to Equity
0.68
Cash Flow Metrics
Revenue & Profitability Trend
Tata Chemicals Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 147.8B | 153.0B | 166.8B | 125.2B | 100.9B |
Cost of Goods Sold | 36.8B | 35.8B | 41.5B | 32.9B | 29.6B |
Gross Profit | 111.0B | 117.2B | 125.3B | 92.3B | 71.3B |
Gross Margin % | 75.1% | 76.6% | 75.1% | 73.7% | 70.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 32.8B | 27.9B | 27.5B | 22.9B | 18.3B |
Other Operating Expenses | 39.1B | 42.3B | 42.6B | 31.1B | 24.2B |
Total Operating Expenses | 71.9B | 70.1B | 70.1B | 54.0B | 42.5B |
Operating Income | 8.3B | 19.4B | 29.9B | 15.4B | 7.7B |
Operating Margin % | 5.6% | 12.7% | 17.9% | 12.3% | 7.6% |
Non-Operating Items | |||||
Interest Income | 450.0M | 1.4B | 750.0M | 1.2B | 747.6M |
Interest Expense | 4.7B | 4.3B | 3.2B | 2.3B | 2.9B |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 5.2B | 8.3B | 27.4B | 16.7B | 6.3B |
Income Tax | 1.7B | 3.8B | 2.9B | 2.7B | 2.0B |
Effective Tax Rate % | 32.1% | 45.9% | 10.5% | 16.0% | 31.2% |
Net Income | 3.9B | 4.4B | 24.3B | 14.0B | 4.4B |
Net Margin % | 2.6% | 2.8% | 14.6% | 11.2% | 4.3% |
Key Metrics | |||||
EBITDA | 21.9B | 30.7B | 39.2B | 26.7B | 16.1B |
EPS (Basic) | ₹9.23 | ₹10.52 | ₹90.95 | ₹49.37 | ₹10.06 |
EPS (Diluted) | ₹9.23 | ₹10.52 | ₹90.95 | ₹49.37 | ₹10.06 |
Basic Shares Outstanding | 254756278 | 254756278 | 254756278 | 254756278 | 254756278 |
Diluted Shares Outstanding | 254756278 | 254756278 | 254756278 | 254756278 | 254756278 |
Income Statement Trend
Tata Chemicals Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.5B | 4.2B | 5.1B | 7.6B | 6.9B |
Short-term Investments | 8.5B | 8.2B | 14.1B | 18.5B | 22.7B |
Accounts Receivable | 19.0B | 19.0B | 26.3B | 19.3B | 14.0B |
Inventory | 25.6B | 25.2B | 25.3B | 22.9B | 16.9B |
Other Current Assets | 780.0M | 1.2B | 2.6B | 2.9B | 557.5M |
Total Current Assets | 67.2B | 63.7B | 81.6B | 87.4B | 66.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 4.3B | 3.8B | 3.5B | 3.2B | 2.9B |
Goodwill | 130.4B | 127.9B | 126.8B | 118.8B | 115.8B |
Intangible Assets | 85.4B | 84.1B | 83.8B | 78.5B | 76.6B |
Long-term Investments | 10.0M | 10.0M | 80.0M | 30.0M | 180.2M |
Other Non-Current Assets | 230.0M | 220.0M | 180.0M | 180.0M | 124.9M |
Total Non-Current Assets | 310.6B | 303.9B | 269.2B | 251.0B | 216.9B |
Total Assets | 377.8B | 367.6B | 350.8B | 338.4B | 283.4B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 25.1B | 23.7B | 26.0B | 24.4B | 16.8B |
Short-term Debt | 22.6B | 22.7B | 6.2B | 31.6B | 15.4B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 560.0M | 190.0M | 370.0M | 210.0M | 120.9M |
Total Current Liabilities | 61.4B | 60.6B | 49.0B | 71.0B | 44.6B |
Non-Current Liabilities | |||||
Long-term Debt | 48.2B | 32.9B | 56.8B | 38.6B | 53.9B |
Deferred Tax Liabilities | 25.4B | 23.8B | 19.4B | 20.4B | 15.7B |
Other Non-Current Liabilities | 600.0M | 590.0M | 600.0M | 300.0M | 321.7M |
Total Non-Current Liabilities | 91.4B | 75.9B | 95.4B | 75.9B | 87.3B |
Total Liabilities | 152.8B | 136.4B | 144.4B | 146.9B | 131.9B |
Equity | |||||
Common Stock | 2.6B | 2.6B | 2.6B | 2.6B | 2.5B |
Retained Earnings | 92.8B | 92.6B | 95.8B | 76.2B | 62.5B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 225.0B | 231.1B | 206.4B | 191.6B | 151.4B |
Key Metrics | |||||
Total Debt | 70.7B | 55.6B | 63.0B | 70.2B | 69.3B |
Working Capital | 5.8B | 3.1B | 32.6B | 16.5B | 21.8B |
Balance Sheet Composition
Tata Chemicals Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 5.7B | 8.2B | 27.2B | 16.8B | 6.3B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -1.3B | 7.9B | -7.5B | -14.9B | 3.0B |
Operating Cash Flow | 11.3B | 19.1B | 23.5B | 4.5B | 13.4B |
Investing Activities | |||||
Capital Expenditures | -19.5B | -18.2B | -15.4B | -12.6B | -12.3B |
Acquisitions | - | - | - | - | - |
Investment Purchases | -50.6B | -38.3B | -46.7B | -50.6B | -41.2B |
Investment Sales | 49.2B | 45.3B | 47.9B | 52.2B | 40.2B |
Investing Cash Flow | -19.4B | -11.8B | -10.4B | -9.3B | -12.3B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -3.8B | -4.5B | -3.2B | -2.6B | -2.8B |
Debt Issuance | 37.5B | 19.6B | 38.9B | 29.9B | 42.4B |
Debt Repayment | -26.9B | -31.1B | -50.9B | -30.3B | -48.7B |
Financing Cash Flow | 19.3B | -18.0B | -15.1B | -2.9B | -9.1B |
Free Cash Flow | -2.4B | 11.8B | 13.9B | 3.7B | 8.0B |
Net Change in Cash | 11.3B | -10.8B | -2.1B | -7.7B | -8.1B |
Cash Flow Trend
Tata Chemicals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
75.76
Forward P/E
19.18
Price to Book
1.12
Price to Sales
1.65
PEG Ratio
19.18
Profitability Ratios
Profit Margin
2.27%
Operating Margin
9.92%
Return on Equity
2.17%
Return on Assets
0.62%
Financial Health
Current Ratio
1.09
Debt to Equity
31.43
Beta
0.48
Per Share Data
EPS (TTM)
₹12.49
Book Value per Share
₹847.63
Revenue per Share
₹581.54
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
tatachem | 244.5B | 75.76 | 1.12 | 2.17% | 2.27% | 31.43 |
Navin Fluorine | 253.7B | 67.57 | 9.09 | 10.99% | 13.90% | 55.85 |
Deepak Nitrite | 248.9B | 35.34 | 4.57 | 13.61% | 8.42% | 23.36 |
Deepak Fertilisers | 185.6B | 18.90 | 2.98 | 14.93% | 9.21% | 66.40 |
Epigral | 79.2B | 18.08 | 4.15 | 18.78% | 17.26% | 31.11 |
Archean Chemical | 76.6B | 48.78 | 4.11 | 8.70% | 14.05% | 12.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.